PBS changes: new oral therapy for melanoma & restrictions on antibiotic repeat scripts

PBS access has been widened to include an oral therapy for melanoma patients. From 1 April the targeted oral combination therapy of encorafenib (Braftovi) plus binimetinib (Mektovi) is PBS subsidised to treat adult patients with unresectable Stage III or Stage IV malignant melanoma with a BRAF V600 mutation. The combination therapy has been shown to ...

Already a member?

Login to keep reading.

© 2021 the limbic